《阿斯利康(AstraZeneca):2022年可持续发展报告(英文版)(35页).pdf》由会员分享,可在线阅读,更多相关《阿斯利康(AstraZeneca):2022年可持续发展报告(英文版)(35页).pdf(35页珍藏版)》请在三个皮匠报告上搜索。
1、SustainabilityReport2022AssuranceBureau Veritas has provided limited assurance for sustainability activities reported in the Sustainability Data Summary 2022 and in the Annual Report 2022.Details are described in the Letters of Assurance,which are publicly available.Assurance is in accordance with t
2、he International Standard on Assurance Engagements(ISAE)3000(Revised),Assurance Engagements Other than Audits or Reviews of Historical Financial Information,and with International Standard on Assurance Engagements 3410 Assurance Engagements on Greenhouse Gas Statements(ISAE 3410),issued by the Inter
3、national Auditing and Assurance Standards Board.AstraZeneca has reported the information cited in this GRI content index for the period from 1 January 2022 to 31 December 2022,with reference to the GRI Standards.Next generation therapeutics Advancements in biotechnology have expanded our toolkit of
4、drug modalities.This provides an opportunity to design therapeutics for disease mechanisms previously considered difficult,if not impossible,to target and enables our scientists to pioneer new approaches to drug discovery.ContentsFootnotes 35This is our eighth annual sustainability report and it des
5、cribes our approach and progress from 1 January 2022 to 31 December 2022,unless otherwise stated.The content is based on those sustainability focus areas deemed material through comprehensive stakeholder engagement and analysis.Allour business operations worldwide are in scope regardless of their fu
6、nction,unlessotherwise stated.Online resources:AstraZeneca Sustainability Data Summary:provides performance measures and targets with at least three years of data,where available,and a United Nations Sustainable Development Goals index.AstraZeneca Sustainability webpages:cover additional topics of i
7、nterest to our stakeholders.Infographics:show our processes and practices.Policies and company standards:state our positions and guidance on key topics.2022 Annual Report:includes how sustainability is integrated across our business model and our riskmanagement.Sustainability overview 3Message from
8、the Chief Executive Officer(CEO)3What sustainability means at AstraZeneca 42022 performance highlights 5About us 6Contribution to the Sustainable Development Goals 7Sustainability governance 8Stakeholder engagement 9Access to healthcare 10Overview 11Equitable access 12Affordability and pricing 14Hea
9、lth system resilience 16Environmental protection 18Overview 19Ambition Zero Carbon 20Product sustainability 23Natural resources 25Ethics and transparency 27Overview 28Ethical business culture 29Inclusion and diversity 31Workforce safety and health 33About this reportAstraZeneca Sustainability Report
10、 2022 2Sustainability overviewSustainability overviewEnvironmental protectionEthics and transparencyAccess to healthcareFootnotesCaption placeholder:Ulpa alis volo del ipis et esto maximus aut landi blauditatem necaboritat laborrum lis volo del ipisut landi blauditatem laborrum.Putting health at the
11、 heart of a sustainable future As we navigate current socio-economic and environmental challenges,we must prioritise building sustainable,resilient and equitable health systems that protect current and future generations.During 2022,AstraZeneca demonstrated its continued commitment to innovate for p
12、atients and improve health outcomes worldwide.Our pandemic response and global vaccine delivery are testament to this,with over six million lives saved in the first year1 and a focus on equitable access.I am equally proud of our efforts to address climate change,the greatest public health crisis of
13、our time,which is causing a rise in chronic diseases and health inequalities,as well as increasing pressures on health systems.As highlighted in this Report,we are making important progress with our science-led Ambition Zero Carbon strategy.By the end of December 2022,we had achieved a 59.3%reductio
14、n in Scope 1 and 2 greenhouse gas(GHG)emissions compared to our 2015 baseline,with our AZ Forest programme working in parallel to help restore nature and biodiversity,and over 10.5 million trees planted since 2020.We also continued to drive change across the health sector,including through the Susta
15、inable Markets Initiative(SMI).Ahead of COP27,the SMI Health Systems Task Force,which I am honoured to champion,announced shared commitments and actions to reduce emissions in line with the 1.5C pathway and accelerate the transition to net-zero health systems.Pascal Soriot,AstraZeneca CEO and Champi
16、on of the Sustainable Markets Initiative(SMI)Health Systems Task Force speaking at COP27,Egypt 2022.Message from the CEOInaugurating a Green Field Hospital with the Egyptian Health Authority during COP27 to support sustainable healthcare delivery.Furthermore,the Partnership for Health System Sustain
17、ability and Resilience(PHSSR),which we co-founded in 2020,has now expanded to more than 30 countries.Our top three ranking in the 2022 Access to Medicine Index recognises our strategic focus on increasing equitable and affordable access to life-changing treatments.How we achieve results is of vital
18、importance,and we are guided by our Values in all that we do.Through our Code of Ethics and standards,we strive for a safe,responsible and ethical business culture for our employees and partners.We also take pride in championing a culture of inclusion and belonging,recognising the power of diversity
19、 in fostering innovation.2023 will see us further accelerate our efforts in delivering our sustainability goals.By working with others to prioritise health,we will play our part in ensuring communities and societies thrive,economies prosper,and the planet recovers.Pascal Soriot,AstraZeneca CEOAstraZ
20、eneca Sustainability Report 2022 3Sustainability overviewSustainability overviewEnvironmental protectionEthics and transparencyAccess to healthcareFootnotesHealthy planetHealthy peopleHealthy societyEthics and transparencyAccess to healthcareEnvironmental protectionSustainabilityat AstraZenecaBuildi
21、ng a healthyfuture for people,society,and the planet Our ambitions Increasing access to life-saving treatments,promoting prevention,and strengthening global healthcare resilience and sustainability.Accelerating the delivery of net-zero healthcare,proactively managing our environmental impact across
22、all activities,and investing in nature and biodiversity.Ensuring ethical,open,and inclusive behaviour across our organisation and value chain.Our sustainability strategy The results of our 2021 materiality assessment identified the issues that matter most to AstraZeneca and our stakeholders,and show
23、ed where we can have a positive impact.We have nine focus areas,each with their own targets,grouped under three interconnected priorities:Access to healthcareEnvironmental protectionEthics and transparencySustainability at AstraZeneca means harnessing the power of science and innovation and our glob
24、al reach to build a healthy future for people,society,and the planet.We are playing our part in tackling the biggest challenges of our time,from climate change to access to healthcare and disease prevention.By using a science-led approach and ensuring we act with integrity and in accordance with our
25、 Values,we are transforming the future of healthcare and making a positive impact.We seek to create value beyond the impact of our life-changing medicines,by embedding sustainability into everything we do from the lab to the patient.What sustainability means at AstraZeneca AstraZeneca Sustainability
26、 Report 2022 4Sustainability overviewSustainability overviewEnvironmental protectionEthics and transparencyAccess to healthcareFootnotes2022 performance highlights14public&private sector organisations convened by AstraZeneca CEO through the SMI to accelerate transition to net-zero health systems87%o
27、f employee survey respondents say that they understand their contributions to our sustainability priorities25/27 of sustainability targets in Sustainability Data Summary are On planSustainability strategy 126,684healthcare workers trained since 2010(cumulative)12.83 millionpeople reached through our
28、 patient assistance programmes(cumulative)Access to healthcare44.63 millionpeople reached through access to healthcare programmes(cumulative)59.3%reduction in Scope 1 and 2 greenhouse gas emissions 18.6%reduction in our waste18.7%reduction in our water useEnvironmental protection(changes are from 20
29、15 baseline)49.5%senior middle management roles held by women83%of employee survey respondents feel we have a speak up culture8 countrieswith supplier diversity programmesEthics and transparencyAstraZeneca Sustainability Report 2022 5Sustainability overviewSee Sustainability Data Summary forfull met
30、rics and methodologySustainability overviewEnvironmental protectionEthics and transparencyAccess to healthcareFootnotesOur ValuesWe follow the scienceWe put patients firstWe play to winWe do the right thingWe are entrepreneurialOur strategic prioritiesScience&InnovationGrowth&Therapy Area Leadership
31、People&SustainabilityOur recognition3rd in 2022 Access to Medicine Index,1st for product deliveryA list for Climate and Water SecurityWorld and Europe Global constituent Dow Jones Sustainability IndexFTSE4Good DiversityInc Top 50 Companies for Diversity List(US)About usOur purpose:We push the bounda
32、ries of science to deliver life-changing medicines.To transform healthcare for billions of people,we are focused on:Science and innovation to deliver new medicines that address unmet medical need Transforming outcomes for patients,increasing access to healthcare,and making healthcare systems more re
33、silient,while growing the success of our company Contributing sustainably to people,society,and the planetOur strategic priorities drive our efforts,while working inclusively and collaboratively across our company and with others,always in line with our Values.Bloomberg Gender-Equality Index 4,000Ce
34、ntral and South America16,500US1,200Canada10,700UK7,100Sweden11,400Other Europe 2,000Russia2,400Middle East and Africa16,500China3,500Japan7,200Other Asia Pacific1,000Australia and New ZealandStrategic R&D centres:Cambridge,UK(HQ);Boston,MA,US;Gaithersburg,MD,US;Gothenburg,Sweden83,500 employees wor
35、ldwideEmployees by reporting regionEurope 38%Emerging markets 35%US 20%Established rest of the world 7%Other R&D centres and offices:San Francisco,CA,US;New York,NY,US;New Haven,CT,US;Alderley Park and Macclesfield,UK;Shanghai,China;Osaka,Japan.AstraZeneca Sustainability Report 2022 6Sustainability
36、overviewSustainability overviewEnvironmental protectionEthics and transparencyAccess to healthcareFootnotesContribution to the Sustainable Development Goals(SDGs)SDG 3|Good health and wellbeing3.4 Reduce premature mortality from non-communicable diseases(NCDs)1,258 health facilities activated(cumula
37、tive)through Healthy Heart Africa programme NCD prevention information reached 39 countries through our Young Health Programme3.6 By 2030,halve the number of global deaths and injuries from road traffic accidents Driver safety:49%reduction in collision rate since 20153.8 Achieve universal health cov
38、erage More than 12.8 million people reached by patient access programmes(cumulative)More than 44.6 million people reached through healthcare programmes(cumulative)3.c Substantially increase health workforce in developing countries More than 126,000 healthcare workers trained(cumulative)SDG 5|Gender
39、equality 5.5 Ensure womens full and effective participation and equal opportunities for leadership at all levels of decision-making in political,economic and public life 49.5%senior middle management roles held by women 38.5%of Board of Directors occupied by women Approximately 1,000 employees atten
40、ded our dedicated leadership development programmes for women2SDG 6|Clean water and sanitation 6.3 By 2030,improve water quality by reducing pollution,eliminating dumping and minimising release of hazardous chemicals and materials 100%of Active Pharmaceutical Ingredients(API)discharges from AstraZen
41、eca sites and 92%of discharges from direct suppliers were in compliance with target36.4 By 2030,substantially increase water-use efficiency across all sectors and ensure sustainable withdrawals and supply of freshwater to address waterscarcity 18.7%reduction in water use since 2015 baselineSDG 8|Dec
42、ent work and economicgrowth 8.8 Protect labour rights and promote safe and secure working environments for all workers 72%reduction in reportable injury rate since 2015SDG 12|Responsible consumption and production 12.2 Achieve the sustainable management and efficient use of natural resources 67%of n
43、ew products have met their defined resource efficiency targets at launch since 201512.5 By 2030,substantially reduce waste generation through prevention,reduction,recycling and reuse 18.6%decrease in total waste generation from 2015 baseline In 2022,avoided 2,129 tonnes of waste by selling it as a b
44、y-productSDG 13|Climate action 13.2 Integrate climate change measures into national policies,strategies and planning Reduced Scope 1 and 2 emissions by 59.3%since 2015 baseline Leading Sustainable Markets Initiative(SMI)Health Systems Task Force to accelerate the transition to net-zero health system
45、sSDG 7|Affordable and cleanenergy 7.3 By 2030,double the global rate of improvement in energy efficiency 89.7%increase in energy productivity(million US dollars of revenue per GWh energy consumption)from a 2015 baseline Reduced energy use by 14.4%since 2015 baselineSDG 17|Partnership for the goals 1
46、7.17 Encourage and promote effective public,publicprivate and civil society partnerships PHSSR continues to expand and act as a driver for policy improvements in the countries where it is activeSDG 15|Life on land Over 10.5 million trees planted since 2020 through AZ Forest 97.5%of paper-based produ
47、ct packaging materials used were supplied from sustainable sources4The 17 United Nations SDGs are a global call to action to address poverty,injustice,and inequality,while tackling climate change.To evaluate our contribution we have mapped how our progress and metrics impact the SDG targets.AstraZen
48、eca Sustainability Report 2022 7Sustainability overviewSustainability overviewEnvironmental protectionEthics and transparencyAccess to healthcareFootnotesSustainability governanceOur sustainability strategy is developed by our Senior Executive Team(SET)with governance provided by our Board of Direct
49、ors and relevant Board Committees,in particular the Board Sustainability Committee,which assesses progress and helps ensure we move forward in the most impactful way.In 2021,the Board established a Sustainability Committee to monitor the implementation of our sustainability strategy,oversee communic
50、ation of sustainability activities with stakeholders,and provide input to the Board and other Board Committees on sustainability matters.During 2022,the Committee held two formal meetings and considered topics such as:embedding sustainability across AstraZeneca,including in the product lifecycle;rev
51、iewing how environmental,social and governance(ESG)risks are managed;reviewing the enterprise-wide approach to our Access to healthcare strategy;and supporting work on the compensation of ESG objectives.In addition,the Committee facilitated a deep dive session for the Board on progress against our A
52、mbition Zero Carbon targets.Committee members also visited AstraZenecas R&D and Manufacturing supply site in Macclesfield,UK,and met with a range of employees working across our sustainability strategic priorities.Board Sustainability CommitteeNazneen RahmanNon-Executive Director of the Board and Ch
53、air of the Sustainability CommitteeAndreas Rummelt Non-Executive Director of the Board Sheri McCoyNon-Executive Director of the BoardMarcus WallenbergNon-Executive Director of the BoardBoard of DirectorsThe AstraZeneca Board of Directors approves our sustainability strategy and reviews our internal
54、sustainability scorecard each quarter.Leif Johansson Non-Executive Chair of the BoardPascal SoriotCEO and Executive Director of the BoardSenior Executive Team(SET)The SET,led by our CEO,develops our sustainability strategy and is accountable for specific sustainability initiatives.They review our in
55、ternal sustainability scorecard each quarter.In 2022,the EVP Sustainability and Chief Compliance Officer was responsible for the overall sustainability strategy execution,including measuring progress on targets and working with leaders to ensure alignment with business priorities.Katarina AgeborgEVP
56、,Sustainability and Chief Compliance Officer,President AstraZeneca AB,SwedenPascal SoriotCEO and Executive Director of the BoardWith effect from January 2023,on the retirement of the EVP Sustainability and Chief Compliance Officer,responsibility for Sustainability passed to our EVP Operations,Inform
57、ation Technology and Sustainability.AstraZeneca Sustainability Report 2022 8Sustainability overviewSustainability overviewEnvironmental protectionEthics and transparencyAccess to healthcareFootnotesWe value the diverse perspectives of internal and external stakeholders,which help to shape our sustai
58、nability strategy and guide its implementation.We periodically seek input from stakeholders through materiality assessments,as well as through regular engagements.We welcome transparent dialogue through a range of communication channels online,face to face and in groups.Our Code of Ethics supports o
59、ur approach.3 interconnected priority pillars9 material focus areasStakeholder engagement Materiality assessment Our sustainability strategy is guided by the materiality assessment we conducted in 2021,which identified the issues that matter most to AstraZeneca and our stakeholders and showed where
60、we can have a positive impact.We assess the relevance of our strategy and material focus areas annually,through continuous dialogue with our stakeholders and horizon-scanning for emerging sustainability topics.This process confirmed that our existing focus areas remained a priority in 2022.Stakehold
61、er engagement in action Considering the interests of our stakeholders is fundamental to our Sustainability strategy.Foremost among our stakeholder groups as a company are our patients including via patient communities and advocacy groups.Other priority stakeholders are payers including governments,p
62、articularly in relation to access to healthcare,the investor community on ESG matters and healthcare professionals(HCPs),with a focus on development and delivery of medicines.We also work closely with academia and R&D partners across the healthcare and environmental fields,as well as our industry pe
63、ers and other major companies with a shared ambition to tackle sustainability challenges,through global policy and industry forums.We partner with governmental and non-governmental bodies across our sustainability priorities.In addition,our suppliers are key to the achievement of many of our environ
64、mental targets and our commitments to ethical behaviour and transparency.We also aim to have a positive impact in the communities where we operate.Last but not least,we have an extensive process of communication and engagement with our employees,who are critical to the achievement of our sustainabil
65、ity goals.For more details on the interests,engagements,and outcomes of contact with these and other stakeholder groups,please see Connecting with our stakeholders in the Corporate Governance section of our Annual Report(pages 86-88 and 217).Material focus areasWe have nine material focus areas grou
66、ped under three interconnected strategic priority pillars,each of which is detailed in this Report,along with relevant targets,goals and examples of sustainability in action.AstraZeneca Sustainability Report 2022 9Sustainability overviewEquitable accessAffordability and pricingHealth system resilien
67、ceAmbition Zero CarbonProduct sustainabilityNatural resourcesEthical business cultureInclusion and diversityWorkforce safety and healthAccesstohealthcareEnvironmentalprotectionEthicsandtransparencySustainability overviewEnvironmental protectionEthics and transparencyAccess to healthcareFootnotesCont
68、ributing to the Sustainable Development Goals,a universal blueprint for prosperity forpeople and the planet,now and intothe future.SDG 3|Good health and wellbeingSDG 17|Partnerships for the goalsSee Sustainability Data Summary forfull metrics and methodology126,684healthcare workers trained(cumulati
69、ve)3 44.63 millionpeople reached through access to healthcare programmes(cumulative)112.83 millionpeople reached though our patient assistance programmes(cumulative)22022 performanceOur material focus areas3,899total healthcare facilities activated4Access to healthcareOur ambitionTo promote preventi
70、on,increase access to life-saving treatments,and strengthen global healthcare resilience and sustainabilityConnection to healthInnovative and sustainable healthcare solutions are essential to improving global health outcomesHealth is key for people and our planet to thrive Access to healthcareAstraZ
71、eneca Sustainability Report 2022 10Equitable accessAffordability and pricingHealth system resilienceSustainability overviewAccess to healthcareEnvironmental protectionEthics and transparencyFootnotesWe want to transform healthcare to secure a future where all people have access to affordable,sustain
72、able,and innovative healthcare.The big picture Everyone should have access to healthcare,no matter who they are or where they live.This is critical across the patient care pathway from prevention,early detection and diagnosis to the effective treatment of disease.ApproachWe are working to remove bar
73、riers to access and innovating to deliver our life-changing medicines in a sustainable and equitable way,through global,regional and local partnerships.Central to this is our commitment to promoting prevention,increasing access to treatments,and strengthening global health system resilience and sust
74、ainability.In 2022,the Access to Medicine Foundation recognised AstraZeneca as third overall out of the 20 companies on the 2022 Access to Medicine Index,and first for Product Delivery,with second place for Governance of Access and sixth for Research and Development,our highest ranking to date.We ar
75、e focused on:Innovating to deliver life-changing medicines and future-proof global health systems Partnering to improve health equity for patients now and in the long-term Transforming healthcare to secure a future where all people have equitable access to treatmentGovernanceWe collaborate on our Ac
76、cess to healthcare material focus areas on a cross-functional basis to deliver our strategy and measure progress.Access to healthcare overviewMaterial focus areas3rdout of 20 companies on the 2022 Access to Medicine IndexAstraZeneca Sustainability Report 2022 11Access to healthcare overviewEquitable
77、 accessAffordability and pricingHealth system resilienceSustainability overviewAccess to healthcareEnvironmental protectionEthics and transparencyFootnotesApproachAstraZeneca is committed to improving equitable access to healthcare for patients globally,including to our innovative product portfolio.
78、Our approach includes integrating programmes into local systems and delivering affordable medicines to patients.We seek to drive positive global health outcomes by:Addressing unmet medical need and barriers to access Increasing the speed and breadth of patient access Driving excellence in product li
79、fe cycle management Understanding the long-term impacts of scientific advances We are playing our part to address health inequities and eliminate discrimination from the delivery of healthcare.As a company at the forefront of scientific and medical innovation,we are also harnessing the latest digita
80、l technologies to support improved access.This includes using the power of data and analytics for early diagnosis,and expanding access to the latest medical research and training for healthcare professionals.Diversity in clinical trials We are committed to designing clinical programmes with equity a
81、t the forefront from idea inception to patient care.Our approach includes increasing the diversity of clinical trial participants so trials better reflect the patients who may use our medicines,which ensures we have a robust and reliable body of evidence.Rare diseases Therapies are only available fo
82、r 5%of more than 7,000 rare diseases.5 We believe people with rare diseases deserve the same attention and investment into finding therapies as anyone else.We supply medicines for rare diseases through our patient support and expanded access programmes and are working to expand the geographies where
83、 our rare disease medicines are available.ChallengesIn every society,economic and supply barriers as well as geographic impediments inhibit universal access to high quality evidence-based healthcare.In developing countries there is an epidemiological shift from the prevalence of communicable to non-
84、communicable diseases,6 but local healthcare provision varies in quality,and the systems may not be in place to tackle this growing burden.Programmes to control priority public health conditions also need to recognise the importance of the economic and social determinants of health.We have therefore
85、 aligned our access initiatives towards improving health equity by addressing two specific local needs:1.Creating holistic approaches to localisation,which includes collaboration with governments and utilising local expertise to identify and address shared priorities.2.Collaborating in cross-sector
86、partnerships to improve health outcomes.Key targets and progressWhy it mattersYour health should not be determined by who you are,where you live or where you were born.We are working to remove barriers to healthcare and give everyone the chance to be as healthy as possible.DescriptionEmbed practices
87、 into the product portfolio to drive equitable access to healthcare including digital health,clinical trial diversity,patient centricity,investing in rare diseases,open innovation,and Intellectual Property(IP)sharing arrangements.Equitable access44.63 millionpeople reached1Total community investment
88、,sponsorships,partnerships and charitable donations(not including Patient Assistance Programmes).7In 2022,$108.06m2022 updatePhilanthropyReach 50 million people(cumulative)through Healthy Heart Africa,Young Health Programme(YHP),and Healthy Lung programme.Status:On planMore than 44.63 million people
89、 reached(cumulative)through Healthy Heart Africa,Young Health Programme and Healthy Lung programme.12022 update2025 targetAstraZeneca Sustainability Report 2022 12Equitable accessSee Sustainability Data Summary forfull metrics and methodologySustainability overviewAccess to healthcareEnvironmental p
90、rotectionEthics and transparencyFootnotesSustainability in actionInterconnected and dynamic global network of health innovation hubs Our A.Catalyst Network is comprised of more than 20 AstraZeneca health innovation hubs,combining physical locations and virtual partnerships.Our collective ambition is
91、 to:Address current healthcare challenges Increase affordable and equitable access to healthcare Scale and showcase patient-enabled innovation through partnerships within the health ecosystemThe network embodies AstraZenecas commitment to advancing cutting-edge science and building a sustainable fut
92、ure,acting as a catalyst to develop life-changing solutions for patients.In 2022,we expanded the network by adding new hubs in Colombia,Peru and Spain.In 2022,over 2 million patients were reached across the A.Catalyst Network through innovative solutions.Project Heart Beat,using India-based Tricog H
93、ealths InstaECG machine enabling local HCPs to upload electrocardiograms(ECGs)to the cloud,where the data are interpreted by specialists using a purpose-built app.If the screening process confirms the diagnosis of a heart attack,the patient is referred to an appropriate health facility.On average,de
94、tection using this technology takes just three minutes,and has helped doctors at poorly equipped primary healthcare centres to correctly diagnose 44,235 patients with a total of 21,348 cases of myocardial infarction identified and referred to tertiary care centres for appropriate intervention by car
95、diologists.Fuel Africa,a health innovation programme launched by Futurize in partnership with AstraZeneca and Microsoft,and co-funded by Bristol Myers Squibb and Famfa Oil,is making connections across African universities via a virtual,immersive programme and competition to create new healthcare sol
96、utions.Harnessing digital technology has helped to create one of the largest cross-university and international innovation programmes in Africa,turning students into entrepreneurs who are generating digital healthcare solutions.In 2022,we connected 1,200 students from 12 universities in seven Africa
97、n countries.Leading role in the response to COVID-19 pandemicThe COVID-19 pandemic accelerated the science behind vaccines and preventative medicines.We have delivered billions of doses of a COVID-19 vaccine to more than 180 countries across the world and on an equitable basis,supplying our vaccine
98、at cost during the pandemic.We were also the first manufacturer to join the COVAX facility working for equitable access to COVID-19 vaccines.A modelled outcomes analysis conducted by health analytics firm Airfinity in July 2022,based on data from Imperial College,London,showed that the AstraZeneca C
99、OVID-19 vaccine is estimated to have helped save over six million lives in the first year of vaccination.8Supporting“last mile”communities in KenyaIn 2022,we launched an initiative in collaboration with the Kenya Ministry of Health,partnering with Amref Health Africa to deploy Mobile Vaccination Cli
100、nics(MVCs)to help protect hard-to-reach communities from the pandemic.The 10 MVCs will supply COVID-19 vaccines and other health services,increasing vaccine access and uptake,and providing education,screening,and care.By the end of 2022,six MVCs were ready for use and 10,700 people had been vaccinat
101、ed since launch.The clinics are equipped with back-up solar power and solar-powered fridges,which reduces their environmental impact and maximises freedom of movement into the heart of communities.Data is reported through on-site web-enabled computers.The clinics will bolster health system infrastru
102、cture preparedness and resilience in Kenya,through the provision of services to those in need and in response to increasing prevalence of non-communicable diseases(NCDs).Improving access to digital solutionsIn 2022,we joined the World Economic Forums EDISON Alliance,a public-private partnership that
103、 aims to improve the lives of 1 billion people through digital inclusion by 2025,with a focus on underserved communities.Our contribution to the 1 Billion Lives Challenge comes from the A.Catalyst Network flagship project in partnership with Qure.ai.We have committed to screen 5 million patients for
104、 lung cancer using AI-based technology,and we have analysed approximately 128,000 scans for lung cancer risk across 25 countries,with high malignancy risk lung nodules identified in 1.6%of scans(as at end December 2022).Our A.Catalyst Network collective ambition is to address current healthcare chal
105、lenges,increase affordable and equitable access to healthcare,and scale and showcase patient-enabled innovation through partnerships.AstraZeneca Sustainability Report 2022 13Equitable accessSustainability overviewAccess to healthcareEnvironmental protectionEthics and transparencyFootnotesApproach Th
106、ere are four key principles that drive sustainable affordability:Sustainability:of both the healthcare system and our research-led business model Value:reflects the clinical benefit of our medicines to patients,and the broader impact on society,along with the positive economic impact to the healthca
107、re system by reducing the need for additional medical intervention Access:collaboration with payers and providers on solutions to enable sustainable access to our medicines Flexibility:in pricing to reflect variation in health system needs and ability to payValue-based agreements:across multiple the
108、rapy areas Value-based agreements enable patient access while reducing uncertainty of payers(clinical or economic)by linking access,reimbursement,or price,to real-world clinical benefit or other agreed terms.AstraZeneca works closely with governments to create agreements,based on local real-world da
109、ta,and which are tailored to address unmet needs.Patient access programmes Patient assistance programmes use fully donated product without expectation of payment from the patient for any portion or to access the programme.Our largest Patient Assistance Programme is AZ&Me in the United States,which p
110、rovides eligible patients with AstraZeneca medicines free of charge Patient affordability programmes aim to close the gap in the ability to pay for out-of-pocket patients(paying for their own medicines)and are active in more than 20 low-and middle-income countries(LMICs)9 Challenges As a global comp
111、any with an active presence in some 85 countries and product sales in approximately 130 countries in 2022,most of our key markets have experienced challenges which affect our flexibility to offer discounts and other affordability initiatives.These include pricing controls,reimbursement mechanisms an
112、d cost-containment measures,plus a high frequency of regulatory changes.We continue to expect downward pressure on prices,affecting the profitability levels of our medicines in various markets.In addition,supply chain complexity increases costs,and the economic downturn is adversely affecting abilit
113、y to pay(where applicable).There are also obstacles such as rising prices for new medicines;shortages and stock-outs,especially to treat NCDs,and a growing problem of counterfeit medicines entering the supply chain.Progress highlightsWhy it mattersWe are committed to addressing barriers to access an
114、d affordability.Industry,policymakers,and payers need to work together to identify solutions.Through collaborations,partnerships,and stakeholder coalitions we are working to ensure essential and innovative medicines become more widely available.Our tailored access strategies were recognised by the 2
115、022 Access to Medicine Index as industry-leading in the Product Delivery category.DescriptionDrive accessibility of medicines for diverse,equitable,and inclusive patient groups,through company policy and programming,including core pricing principles and access programmes.Affordability and pricingGlo
116、bal patient affordability programmes reached more than 1.27 million patientsfunded by AstraZeneca.10through patient assistance programmes.111,107 non-profit organisations$3,100.2 million in product donation2022 updateAstraZeneca Sustainability Report 2022 14Affordability and pricingSee Sustainabilit
117、y Data Summary forfull metrics and methodologySustainability overviewAccess to healthcareEnvironmental protectionEthics and transparencyFootnotesSustainability in actionWe now have a view across markets running similar programmes,enabling insights into the performance of different initiatives.This h
118、as raised the standard of internal reporting which provides us with valuable data.Launch of Global Patient Affordability Programmes DashboardIn 2022,with demand increasing for preventative and therapeutic healthcare,we took action to ensure an affordability mindset was embedded alongside our busines
119、s goals.We created an internal Global Patient Affordability Programmes Dashboard,based on reliable,consistent data,that can easily be viewed at global,regional,and country levels.We also generated a bank of success stories to show the range of initiatives being undertaken.The Dashboard enables us to
120、 standardise our approach and provide guidance to expand our affordability programmes,in new countries or disease areas,while learning from best practice sharing.To ensure consistency across the company we aligned on the key performance indicators and definitions.We now have a view across markets ru
121、nning similar programmes,enabling insights into the performance of different initiatives.This has raised the standard of internal reporting which provides us with valuable data to share internally and externally.In 2022,we tracked 158 active programmes across 26 countries,mainly but not exclusively
122、in LMICs,9 reaching more than 1.27 million patients.PUMUA programme expansionOur PUMUA“Breathe”initiative makes low-cost,high-quality respiratory medicines available at a significant discount in selected countries in Africa.The programme also makes respiratory equipment for asthma management availab
123、le in all participating countries.Building on the 800 nebulisation stations activated in 2021 in Kenya,Ghana,Cte dIvoire,Ethiopia,and Senegal,in 2022 an additional 123 nebulisation stations were activated in Cte dIvoire,Senegal and Cameroon.The programme also established Centres of Excellence(COEs)f
124、or asthma care,starting in Kenyatta National Hospital,Kenya.In total,20 COEs were established in Kenya in 2022,for medical and scientific education,patient experience mapping and support.Making genetic testing for ovarian cancer affordable In 2021 we entered into a partnership with diagnostics compa
125、ny AmoyDx to make genetic testing for ovarian cancer more affordable,in order to improve access to testing which identifies homologous recombination deficiency(HRD),a biomarker for cancer.By the end of 2022,we had installed a total of 14 AmoyDX labs for HRD testing in LMICs9 across our International
126、 Commercial region,which together tested 6,220 patients by year end,in addition to 3,915 tested in 2021.805 patients were enrolled in the HALO study,to determine the prevalence of HRD in women with newly diagnosed ovarian cancer,with a positivity rate of 48-50%,thereby identifying more patients that
127、 could benefit from innovative therapies.57 sites were part of the initial study and results are expected in mid-2023.“Nesmet Hawa”a breath of air for children in EgyptIn order to address a gap in home-based care for children with asthma in Egypt,we partnered with Medel,a medical devices company and
128、 the Paediatric Association for Asthma and Nutrition,to launch an initiative to provide access to nebulisers at a significant discount and support affordable access to treatment for asthma.Medel reduced the price of the nebulisers by 50%and AstraZeneca contributed a further 20%,bringing the total di
129、scount to 70%.The programme was launched in March 2021 and by the end of October 2022 had reached 15,000 patients.Awareness of the programme was supported by a campaign launched on digital and media channels.Access to innovative therapies for lung cancerThe focus of this programme was a targeted the
130、rapy for lung cancer,with the objective to optimise access in LMICs9 through an access-driven reimbursement programme.It is based on five core elements:Revisiting the pricing approach to apply a“right pricing model”based on gross price,net price,and tiered pricing Engaging HCPs through education,res
131、ources,outreach,engagement Shaping policy to prioritise support for oncology funding Supporting healthcare systems testing,diagnosis,tumour group establishment,clinics,cold chain support,infusion on site or at home Strengthening marketing company capabilities local commitments to cross-functional pl
132、anning,pricing and access strategyThe initiative has initially been implemented in five markets:Egypt,India,Malaysia,Mexico and Vietnam.Collaborating with the International Market Access team each market has identified local needs,including diagnostics,patient support programmes,resourcing,and capab
133、ility assessment.It will reach more than 10,000 additional patients in the next five years in international markets.AstraZeneca Sustainability Report 2022 15Affordability and pricingSustainability overviewAccess to healthcareEnvironmental protectionEthics and transparencyFootnotesApproach Sustainabl
134、e healthcare for all requires investment in strengthening health systems,to deliver an infrastructure designed to be responsive to the needs of the population it serves.Each of our Access to healthcare focus areas aims to contribute to health system resilience.We are investing in ground-breaking glo
135、bal collaborations,company initiatives,local partnerships and fast-tracked innovation to give access to higher quality healthcare for more people worldwide.Specific activities include:Improving preparedness for future shocks and enhancing international coordination on key processes such as scenario
136、planning,response protocols and reserve capacities Optimising the location and focus of patient care through digital technologies Addressing the social,economic,and ecological costs of disease through targeted prevention measures Improving the effectiveness of care for chronic diseases through defin
137、ing,implementing,and monitoring improved quality of care standards Working with stakeholders on multi-sector prevention and control measures that are optimised to address risk factors and local challenges,while leveraging our experience in health programming We aim to build the capabilities of healt
138、hcare systems to best respond to patient needs by:Ensuring programming is locally and culturally appropriate Using our global footprint to scale partnerships and collaborations Establishing mechanisms for collaboration with our partners,for example through joint coordination,planning,follow up and a
139、greement to a set of core indicators for monitoring and evaluation Challenges The shifting burden of disease,financial and geopolitical crises and the frequency of extreme weather events,all put pressure on health systems.These may range from national or local disruptions to pandemics with substanti
140、al global impact such as COVID-19 and the recent Ebola outbreaks.Increasing the capacity of health systems to respond more quickly and effectively to new challenges may increase health system resilience.We work across the company to develop an innovative product portfolio that drives positive global
141、 health outcomes,and devise access programmes that focus on strengthening healthcare systems through training of healthcare providers.With this approach we respond to the need for medicines and treatments,while also supporting longer-term health system resilience.Key targets and progressWhy it matte
142、rsDuring the COVID-19 pandemic,we saw the need for health systems to adapt to ever-changing societal and economic circumstances to cope with shocks and crisis situations.All while continuing to provide services and deliver improved health outcomes,particularly in LMICs.9DescriptionStrengthen health
143、systems by advocating for health system reform and policy;building capabilities to address unmet medical need,improve access to quality healthcare and provide solutions along a continuum of care from prevention,awareness,diagnosis,and treatment to post-treatment and wellness;and committing to disast
144、er relief,grants,and donations.Health system resilience260,000 young people trained as peer educators in 39 countries through Young Health Programme121,258were activated through our Healthy Heart Africa programme.4Train 170,000 healthcare workers(cumulative)to strengthen health systems throughout th
145、e world through our Healthy Heart Africa and Healthy Lung programmes.Status:On planMore than 126,600 healthcare workers trained(cumulative).32022 update2025 targethealthcare facilities(cumulative)2022 updateHealth facilities activatedAstraZeneca Sustainability Report 2022 16Health system resilienceS
146、ee Sustainability Data Summary forfull metrics and methodologySustainability overviewAccess to healthcareEnvironmental protectionEthics and transparencyFootnotesSustainability in actionLatest PHSSR findings highlight the importance of prioritising prevention and early intervention to strengthen the
147、resilience and sustainability of health systems.Partnership for Health System Sustainability and Resilience(PHSSR)This collaboration between the London School of Economics,the World Economic Forum and AstraZeneca continued its work to strengthen global health systems,now active in over 30 countries
148、worldwide.Joined by other global level partners including Philips,KPMG,WHO Foundation and the Center for Asia-Pacific Resilience and Innovation,the PHSSR continues to expand and act as the driver for policy improvements in the countries where it is active.During 2022,the partnerships in-depth health
149、 system research progressed in 13 new Phase 2 countries,and main findings were presented at the PHSSR Global Summit in November 2022,covering key themes from workforce and health service delivery,finance and governance,to the role of technology in strengthening health systems.These latest findings h
150、ighlight the importance of prioritising prevention and early intervention in NCDs,as well as climate change,to strengthen the resilience and sustainability of health systems.Healthy Heart Africa(HHA)programmeOur HHA programme is committed to reducing hypertension and the burden of cardiovascular dis
151、ease,aiming to reach 10 million people with elevated blood pressure across Africa by 2025.We work with local and global partners to raise awareness and offer training,screening,and reduced cost treatment,where applicable.By the end of 2022,the programme had conducted more than 32 million blood press
152、ure screenings and trained over 10,600 healthcare workers since launch in 2014.In 2022,the programme expanded into Nigeria and entered into a new partnership in Zanzibar.In December,it was announced that the programme will expand into 10 more countries,starting in 2023.The 2022 Access to Medicine In
153、dex recognised the programme as an industry Best Practice in the category“Scaling up inclusive business models to expand access to medicines for non-communicable diseases”.ACT for Cancer CareIn March 2022,we launched Accelerating Change Together(ACT)for Cancer Care,a new coalition which seeks to dri
154、ve equitable access to innovative treatments and screening programmes to detect cancer earlier.In November 2022,we launched Cancer Care Africa under the ACT initiative(ACT;CCA),to address the burden of disease across the continent.Over the next three years,ACT;CCA aims to drive screening and diagnos
155、tics covering one million people across cancer types,and to provide training for more than 10,000 healthcare professionals across 100 oncology centres.Lung Cancer Policy Network launch In 2022,the Lung Ambition Alliance,of which AstraZeneca is a founding member,established the Lung Cancer Policy Net
156、work,an initiative aimed at elevating lung cancer as a policy priority worldwide,which launched with a report and an interactive map.The report,Lung cancer screening:learning from implementation,draws on expertise and experience from local lung cancer screening programmes around the world to outline
157、 how specific challenges have been addressed in practice,with the aim of providing useful guidance for implementation elsewhere.The interactive map,designed to facilitate policy-level discussions,collates research conducted globally on the implementation of non-invasive low dose computed tomography(
158、LDCT)screening which is more precise and uses less radiation than a conventional CT scan enabling users to explore case studies that can inform and promote LDCT implementation in new locations.The map also allows users to compare simple country-level indicators to help build an understanding of the
159、current policy contexts for the early detection of lung cancer.Young Health Programme(YHP)Since 2010,AstraZenecas YHP has empowered young people aged 10 to 24 to make informed choices about their health,to reduce the risk factors that contribute to NCDs such as cancer,diabetes,respiratory and heart
160、disease.In collaboration with our partners around the world,including UNICEF and Plan International,the YHP supports research,advocacy,education and the development of young people.By the end of December 2022,the programme had reached over nine million young people with health information and traine
161、d more than 260,000 young people as peer educators in 39 countries.In 2022,through our partnership with UNICEF,eight policies and laws have been adopted,updated or upheld in six countries to be more protective of adolescent health.Girls Belong HereTo further our commitment to gender and health equit
162、y,our YHP awarded$160,000 in grants to 16 small,women-led non-profit organisations working to improve young peoples health in their communities.We also welcomed over 580 young women from 41 countries into our offices around the world during International Day of the Girl,in collaboration with Plan In
163、ternational,to deepen the awareness of issues perpetuating gender and health inequalities and to provide unique leadership opportunities.Young women stepped into senior leadership positions for a day,shared their views and engaged in discussions on important health and sustainability topics,with man
164、y receiving ongoing mentorships and coaching from our employees.AstraZeneca Sustainability Report 2022 17Health system resilienceSustainability overviewAccess to healthcareEnvironmental protectionEthics and transparencyFootnotesContributing to the Sustainable Development Goals,a universal blueprint
165、for prosperity forpeople and the planet,now and intothe future.SDG 6|Clean water and sanitationSDG 7|Affordable and clean energySDG 12|Responsible consumption and productionSDG 13|Climate actionSDG 15|Life on landSDG 17|Partnerships for the goalsSee Sustainability Data Summary forfull metrics and me
166、thodology10.5 milliontrees planted in Australia,Indonesia,Ghana,US and the UK since 2020 97.5%of paper-based product packaging materials used were supplied from sustainable sources achieving the 2022 target1750+material suppliers with a critical role in patient supply screened to understand climate
167、vulnerability in the upstream value chain for 10 selected medicines480+suppliers partnered with to assess and disclose their greenhouse gas emissions to the CDP Supply Chain programme 2022 performanceOur material focus areasEnvironmental protectionOur ambitionAccelerating the delivery of net-zero he
168、althcare,proactively managing our environmental impact across all activities,and investing in nature and biodiversityConnection to healthSupporting a healthy environment improves health outcomes and helps prevent the onset of certain diseases likely to become more prevalent in a changing climate The
169、 health of the planet impacts all lifeAstraZeneca Sustainability Report 2022 18Environmental protectionAstraZeneca Sustainability Report 2022 18Ambition Zero CarbonProduct sustainabilityNatural resourcesSustainability overviewAccess to healthcareEnvironmental protectionEthics and transparencyFootnot
170、esBeyond the benefits of our medicines to patients,our contribution to society must respect our environment and ensure the sustainable use of the planets finite natural resources.We know that a healthy environment is critical for human health.The big picture Climate change and the degradation of eco
171、systems are already impacting human health and undermining the capacity of health systems.Bold climate action and investments in nature and biodiversity are vital to improve health outcomes.The environmental challenge is multifaceted a systems-level approach is needed to deliver better healthcare ou
172、tcomes with a lower environmental footprint.There is increasing focus on the environmental footprint of goods and services and companies are under greater environmental scrutiny,reinforcing the need to have robust scientific evidence underpinning environmental targets and performance.ApproachAt Astr
173、aZeneca,we manage our Environmental Protection material focus areas in an integrated way.Sustainable product design,sourcing,and manufacturing means lower natural resource use,reduced chemical and water demand,and less waste and pollution,as well as a lower carbon footprint.We are using a science-le
174、d approach to lower the economic and environmental burden of healthcare,while improving health outcomes.To achieve this,we are accelerating the delivery of net-zero healthcare,proactively managing our environmental impact across all activities,and investing in nature and biodiversity.We are demonstr
175、ating that business growth can be achieved while reducing environmental impacts;but there is more to do.By investing in new ways of working and through innovative partnerships,we can maximise the efficiency of how we use natural resources to further reduce our footprint.Through our Ambition Zero Car
176、bon strategy,we are pursuing ambitious decarbonisation targets,accelerating our progress towards net-zero,and managing the risks and opportunities presented by climate change.GovernanceIn addition to our general approach to governance,our executive-led Ambition Zero Carbon Governance Group is accoun
177、table for the delivery of Ambition Zero Carbon.In 2022,this high-level group included our CEO,CFO,the EVP,Sustainability and Chief Compliance Officer,and the EVP,Operations and IT.Since 2021,delivery of Ambition Zero Carbon Scope 1 and 2 commitments has been included in our executive incentive arran
178、gements for the Performance Share Plan(PSP),with a weighting of 10%.Environmental Management System The guide for our Environmental Management System is embedded in our Code of Ethics supported by our Safety,Health,and Environment(SHE)policy standard.Our SHE management system is implemented in line
179、with recognised international standards such as ISO 14001 and 50001.It ensures the environmental risks of our activities are assessed,operational controls are in place,checks are completed through a risk-based audit programme led by an independent organisation and there is an annual management revie
180、w process.Natural Resource Efficiency InvestmentTo drive our climate action initiatives and meet our environmental targets,we have a dedicated Natural Resource Efficiency Fund,which has invested approximately$150 million in environmental efficiency innovations since 2015.This,together with other cen
181、tral capital investments,has seen a further$26.6 million spent2 in 2022,including 31 new projects.Task Force on Climate-Related Financial Disclosures(TCFD)A TCFD steering group with cross-functional membership has oversight of the physical and transitional risks and opportunities posed to AstraZenec
182、a by climate change.The identification and assessment of climate risk forms part of our existing risk management processes.Failure to meet regulatory and ethical expectations on environmental impact,including climate change is a component of the Groups risk landscape but is not currently considered
183、to be a Principal Risk for the Group.We are incorporating climate resilience across our operations and value chain,mitigating the risks,and exploring the opportunities that the transition to a low carbon economy presents to the healthcare sector.Environmental protection overview$150m invested by the
184、 Natural Resource Efficiency Fund in environmental efficiency innovations since 2015Material focus areasAstraZeneca Sustainability Report 2022 19Environmental protection overviewAmbition Zero CarbonProduct sustainabilityNatural resourcesSustainability overviewAccess to healthcareEnvironmental protec
185、tionEthics and transparencyFootnotesApproachWe follow the science and focus our activities on delivering absolute reductions in all our direct and indirect GHG emissions sources across the value chain Scopes 1,2 and 3.Through Ambition Zero Carbon,we are on track to reduce GHG emissions from our glob
186、al operations(Scope 1 and 2)by 98%by 2026 from a 2015 baseline.We were one of the first seven companies to have our net-zero Scope 1-3 targets verified under the Science-Based Targets Initiatives Net-Zero Corporate Standard.We were the first pharmaceutical company to sign up to all three of the foll
187、owing Climate Group initiatives:by the end of 2025 we will reduce absolute energy use and double energy productivity compared with 2015(EP100);we will use 100%renewable energy for electricity(RE100)and heat;and we will maximise our transition to EVs in our road fleet(EV100).We aim to halve our entir
188、e value chain footprint by 2030,on the way to a 90%reduction by 2045 from a 2019 baseline.By 2030 we will become carbon negative for all residual emissions.We are engaging across our entire value chain to measure and reduce our Scope 3 emissions.We have set the goal that by the end of 2025,95%of our
189、 spend in Scope 3 Categories 1(purchased goods and services)and 2(capital goods),and 50%of our spend in Scope 3 categories 4(upstream transportation)and 6(business travel)will be with companies that have science-based targets(SBTs)to limit global warming to 47,000 observations6 reported through AZ S
190、HE SystemDriver safety:55%reduction in collisions per million kilometres driven from 2015 baseline.4Workforce safety:75%reduction in total injury rate from 2015 baseline.4Status:On planStatus:On plan49%reduction in collisions.572%reduction in total injury rate.52022 update2022 update2025 target2025
191、targetAstraZeneca Sustainability Report 2022 33Workforce safety and healthSee Sustainability Data Summary forfull metrics and methodologySustainability overviewAccess to healthcareEnvironmental protectionEthics and transparencyFootnotesSustainability in actionHuman Performance Event Learning trainin
192、g fixing the system not the peopleAs part of our commitment to integrating Human and Organisational Performance(HOP)thinking a science-based approach to understanding how and why people make mistakes and what organisational improvements can be made into our Global Operations organisation in 2022,we
193、provided Human Performance Event Learning(HPEL)practitioner training to over 800 individuals,as well as HOP training for leaders and suppliers globally.The HPEL approach has three main steps:1.Developing an understanding of the events performance context creating a safe environment for learning by r
194、ecognising how mistakes happen,without blame what failed and not who failed.Exploring the background and what error traps and local workplace factors contributed to the event.2.Identifying the required improvements or countermeasures focusing on the importance of learning as part of an improvement s
195、trategy.Going through a process away from procedures and towards error-proofing or elimination of hazards.3.Shared learning identifying the impacts,errors,and the local and organisational factors discovered,capturing key learnings to be shared at site level and beyond.We foster an environment that s
196、upports physical and mental health to make people feel safe,energised and inspired.Preventing Serious Injury and Fatality(SIF)at workWe launched a Serious Injury and Fatality Prevention and Mitigation Programme in 2021,led by our Global SHE team and guided by a senior-level steering committee.Proces
197、s and life safety subject matter experts evaluate high-risk activities with the potential to result in a serious injury or fatality and prioritise these against internal audit findings and past events.In 2022,we implemented the second year of our three-year plan to address 12 high-risk areas,focusin
198、g on work at height,safe operation,contractors and construction safety.As part of the plan,working teams reviewed and uplifted existing standards and materials,followed by a gap assessment at site-level.Gap assessment results were then reviewed by site leadership teams and the steering committee.As
199、a result,a new AstraZeneca Standard on Working at Height was launched towards year end,with additional guidance to support the standard.The scope of the initiative was also extended beyond manufacturing to include major R&D sites.Healthy Mind app supporting mental health worldwide In order to provid
200、e easily accessible support for employee mental health through digital innovation,our Safe Space employee resource group(ERG)worked with our Global IT,and SHE functions to develop a digital solution with Microsoft using Power Platform.This led to the Healthy Mind app,which has been upgraded in 2022
201、with an improved user experience,support for 24 languages and access to mindfulness content.Since launch,the app has been accessed 26,000 times by 16,000 global employees.It is an example of innovative solutions to employee wellbeing,supported by cross-functional and ERG collaboration.Drive Success
202、driver safety campaign to protect employees and communitiesSince our return to the workplace in 2021 and early 2022,we have seen an increase in the number of vehicle collisions reported,prompting a review of our Drive Success driver safety programme.In 2022,a safe driving campaign was developed and
203、endorsed by our Commercial SHE Executive Team,with leadership video content and a messaging cascade for employee engagement.The campaign was aimed at line managers with accountability for SHE.It was designed to initiate team discussions on safe driving habits and to understand any barriers to those
204、habits.Topics included risks to safety such as excessive speed,distractions and fatigue.The campaign emphasised preventive measures that employees and line managers can take to improve safety in these areas.The campaign also included ideas for five-minute safety moments or check-ins,asking teams tho
205、ught-provoking questions to maintain an emphasis on driver safety,with the goal of protecting our employees and the communities in which we work.AstraZeneca Sustainability Report 2022 34Workforce safety and healthSustainability overviewAccess to healthcareEnvironmental protectionEthics and transpare
206、ncyFootnotesFootnotesAstraZeneca Sustainability Report 2022 35FootnotesFootnotesSustainability overview1.WatsonOJ,etalGlobalimpactofthefirstyearofCOVID-19vaccination:a mathematical modelling study.Published online June 23,2022.Available at:https:/ Last accessed:January 2023.Dataestimatesbasedonmodel
207、outcomesfromseparateanalysesconductedbyAirfinityandImperialCollegeLondon,UnitedKingdom.AstraZenecaDataonFile.DoFREF-156573,date of preparation 31 January 2023.2.In2022wehadatotalof9,500employeesgothroughanimmersiveandcohort-basedAZdevelopmentintervention.Forour two dedicated women leader development
208、 programmes(Women as Leaders,Empowerment diversity by design)we had approximately 1,000 women graduate.Our programmes designed forvariousstagesofleadershipsaw8,500participants,witha50:50M/Fsplitrepresented.3.Ensure100%ofAstraZenecasitedischargesand90%ofsupplier site discharges are in compliance with
209、 safe API discharge concentrations.4.Datareportedfor2022isforcalendaryear2021andbasedonweight supplied.Scope includes primary,secondary,and tertiary packaging.Alexion brands excluded.Access to healthcare1.Peoplereachedisdefinedperprogramme,dependingontheoperationsofspecificprogrammes.Thisfigureinclu
210、descurrentprogrammes:Healthy Heart Africa,Young Health Programme,and historic programmes:Healthy Lung Programme and Phakamisa.2.As of the time of publishing the report,there was an 88%response rate from global markets.Cumulative reporting means the remainder will be captured in next years reporting
211、and that people reached may not be unique individuals.3.Thisfigurecomesfromcurrentprogramme:HealthyHeartAfrica,and historic programmes:Healthy Lung Programme,and Phakamasia.4.Total healthcare facilities activated includes current programme:Healthy Heart Africa,and historic programme:Healthy Lung Pro
212、gramme.5.AccordingtoEveryLifeFoundation,93%95%ofmorethan7,000knownrarediseaseshavenoUSFoodandDrugAdministration-approved therapies.https:/everylifefoundation.org/about-us/6.Orach C.G.Health equity:challenges in low incomes countries.PublishedonlineOctober2009.Availableat:http:/www.bioline.org.br/pdf
213、?hs09046 Last accessed:January 2023.7.Methodology update in 2022 means total community investments referstopaymentscompletedwithinthefinancialyear.8.WatsonOJ,etalGlobalimpactofthefirstyearofCOVID-19vaccination:a mathematical modelling study.Published on line June 23,2022.Available at:https:/ Last ac
214、cessed:January2023.DataestimatesbasedonmodeloutcomesfromseparateanalysesconductedbyAirfinityandImperialCollegeLondon,UnitedKingdom.AstraZenecaDataonFile.DoFREF-156573,dateofpreparation31January2023.9.AccordingtoWorldBank,lowermiddle-incomeeconomiesaredefinedasthosewithaGrossNationalIncome(GNI)percap
215、itabetween$1,086and$4,255.WorldBankCountryandLendingGroups Available at:https:/datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups Last accessed:January 2023.10.Includesfinancialdonations,in-kinddonations,productdonations.11.These patient assistance program
216、mes use fully donated product without expectation of payment from the patient for any portion or to access the programme.12.Peopletrainedisdefinedperproject,dependingonthespecificoperations.Peer Educators through YHP refers to young people thatarecapacitatedbytheYHPtotraintheirpeersonNon-Communicabl
217、eDisease(NCD)riskfactors.Environmental protection1.Datareportedfor2022isforcalendaryear2021andbasedonweight supplied.Scope includes primary,secondary,and tertiary packaging.Alexion brands excluded.2.In2022,weinvested$26.6millionthroughourNaturalResourceEfficiencyFundtogetherwithothercentralcapitalin
218、vestments.Aspartofthis,weinvested$21milliononenergyefficiencyandrenewableenergy(SolarPV).3.RomanelloM.etal.ThereportoftheLancetCountdownonhealthand climate change:health at the mercy of fossil fuels.Published onlineOctober25,2022,Availableat:https:/ Last accessed:January 2023.4.Convergence of two ta
219、rgets communicated in 2020 and 2021 for small molecule syntheses and biologics products.5.Datacollectedoneyearinarrears.Scopeis54APIsforwhichdata is available to calculate safe API discharge limits and based on 2021 manufacture and formulation activities.One discharge assessment at a single timepoin
220、t(1/44 measurements)marginally exceeded the safe discharge target(failure in vacuum system and waterusereductioncausinghighconcentrationineffluent,vacuumpromptlyrepaireduponidentificationoffault,allothertimepointsmeasurementswerewithinsafedischargetargets)Oneof66APIdischargesmarginallyexceededthesaf
221、edischargetarget(RQ=1.3 based on application of additional marine assessment factor of 10).6.Targetupdatedin2022toreflectincreasedambitionbefore2025.7.AlmondR.E.A.,GrootenM.,JuffeBignoliD.&PetersenT.(Eds).(2022)LivingPlanetReport2022.WWF,Gland,Switzerland.Online:https:/livingplanet.panda.org/Accesse
222、d 2 February 20238.TaskforceonNature-relatedFinancialDisclosures.Online:https:/tnfd.global/Accessed 2 February 20239.TheScienceBasedTargetsNetwork.Online:https:/sciencebasedtargets.org/about-us/sbtn Accessed 2 February 2023.Ethics and transparency1.Seniormiddlemanagementreferstostaffdirectorleveland
223、above.2.Speak Up question in the internal survey changed from:“I feel comfortable to speak up and express my opinion at work”in 2020 and to“I feel comfortable to speak my mind and express my opinion at work in 2021 and 2022.3.Wedefineour100%completestatisticbysayingallactiveemployeesonthedayofrollou
224、t(inthiscase16/17thOctober)must complete the course.Active employees are those not impactedbyvariablessuchasparentalleave,long-termsicknessand garden leave.4.Target excludes Alexion.5.The inclusion criteria for injuries and occupational illnesses in the metrics reported here are aligned with the US
225、Occupational Safety andHealthAdministration(OSHA)RecordKeepingRule.Workforcesafety and health for AstraZeneca and Alexion is reported separately.The Alexion total reportable injury rate(per million hours worked)is0.7.AstraZenecarepresents94%oftotalworkforce,Alexionrepresents6%oftotalworkforce.6.Observations include positive interactions or unsafe conditions.All observations include peer to peer coaching.Sustainability overviewAccess to healthcareEnvironmental protectionEthics and transparencyFootnotes